Effect of zoledronic acid combined with pamidronate disodium in the treatment of lung cancer patients with bone metastasis
Objective:To analyze the clinical effect of zoledronic acid combined with pamidronate disodium in patients with bone metastasis of lung cancer.Methods:From February 2021 to February 2024,100 patients with lung cancer bone metastasis samples admitted to our hospital were selected,and the patients were divided into control group and observation group according to the random number table method,with 50 patients in each group.The control group was treated with zoledronic acid,and the observation group was treated with zoledronic acid+pamidronate disodium.The inflammatory factors[interleukin-6(IL-6),interleukin-8(IL-8),tumor necrosis factor(TNF-α),high-sensitivity C-reactive protein(hs-CRP)],clinical efficacy,adverse reactions and quality of life were compared between the two groups.Results:After treatment,the levels of IL-6,IL-8,TNF-α and hs-CRP in observation group were lower than those in control group(P<0.05).The total effective rate of observation group was 96.00%,which was higher than 80.00%of control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The scores of quality of life in the observation group were higher than those in the control group(P<0.05).Conclusion:Zoledronic acid combined with pamidronate disodium is effective in inhibiting inflammatory factors,improving clinical efficacy and quality of life in patients with lung cancer with bone metastasis,and has high safety.
Zoledronic acidPamidronate disodiumBone metastasis of lung cancer
NETL
NSTL
万方数据
